NovoCure (NVCR) Capital Expenditures Growth (5y) (2019 - 2026)
NovoCure (NVCR) Capital Expenditures Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.44% |
| Mar 31, 2026 | 5.29% |
| Dec 31, 2025 | -3.19% |
| Sep 30, 2025 | 1.80% |
| Jun 30, 2025 | 10.60% |
| Mar 31, 2025 | 27.80% |
| Dec 31, 2024 | 23.96% |
| Sep 30, 2024 | 31.59% |
| Jun 30, 2024 | 36.71% |
| Mar 31, 2024 | 38.35% |
| Dec 31, 2023 | 30.63% |
| Sep 30, 2023 | 39.91% |
| Jun 30, 2023 | 52.01% |
| Mar 31, 2023 | 52.55% |
| Dec 31, 2022 | 3.50% |
| Sep 30, 2022 | 59.99% |
| Jun 30, 2022 | 61.50% |
| Mar 31, 2022 | 37.64% |
| Dec 31, 2021 | 87.37% |
| Sep 30, 2021 | 13.96% |